What is Allogeneic NK Cell Therapy?
Natural killer (NK) cells are part of the innate immune system and are able to identify and respond to abnormal or stressed cells. In allogeneic NK cell therapy, the cells are sourced from a healthy, screened donor rather than from the patient.
Using donor-derived cells can allow for cells to be prepared in advance and, in some cases, offers a robust, highly active NK cell population. Donors and donor material are screened according to established laboratory safety standards.
StemCell Longevita is an international patient coordination platform. We arrange access to a GMP-certified laboratory and experienced clinicians who determine suitability, compatibility, and the administration plan after a thorough medical review.
The Science Behind the Approach
Donor-Derived NK Cells
Cells are obtained from healthy, screened donors and processed under GMP-certified laboratory conditions.
Innate Immune Activity
NK cells can recognize and respond to abnormal cells as part of the body's innate immune defense.
Screening & Compatibility
Donor material undergoes screening, and clinical compatibility is assessed before any administration is planned.
Physician-Directed Administration
Prepared cells are administered in a clinical setting under medical supervision after individual evaluation.
Potential Candidates
Before You Proceed
How the Process Works
Consultation & Medical Review
A specialist reviews your history and records to assess whether allogeneic NK cell therapy may be suitable.
Donor Screening & Matching
Screened donor cells are selected and compatibility is assessed according to laboratory protocols.
GMP Laboratory Preparation
Donor NK cells are prepared and quality-checked in a GMP-certified laboratory prior to administration.
Administration & Follow-Up
Cells are administered under medical supervision, followed by a structured follow-up plan.
Pricing & Personalized Quotes
Because donor sourcing and protocol design are individualized, a personalized quote is provided during your consultation once the clinical team confirms the appropriate approach.
Frequently Asked Questions
Why choose allogeneic over autologous NK cell therapy?
Allogeneic therapy uses screened donor cells, which can be prepared in advance and may provide a highly active NK cell population. The right choice depends on your clinical assessment, and the team will explain the reasoning for the recommended approach.
Are the donor cells screened for safety?
Yes. Donor material is screened according to established laboratory safety standards, and all preparation takes place in a GMP-certified facility.
Will my body reject donor NK cells?
Compatibility is carefully assessed by the clinical team before any administration. Potential risks and how they are managed are discussed during your consultation.
Is this a replacement for conventional treatment?
No. Advanced cell therapies are intended to complement care recommended by your own physician, not to replace it.